Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| ASLAN Pharmaceuticals Limited | Eblasakimab (ASLAN004) - (TREK-DX) | Atopic dermatitis (AD) | Phase 2b | Data Released | Subcutaneous | Immunology |
| ASLAN Pharmaceuticals Limited | Eblasakimab (dupilumab-experienced) | Atopic dermatitis | Phase 2 | Ongoing | Subcutaneous | Immunology |
| ASLAN Pharmaceuticals Limited | Varlitinib - (TREETOPP) | Biliary tract cancer | Phase 2/3 | Trial Discontinued | Oral | Oncology |
| ASLAN Pharmaceuticals Limited | Varlitinib | Gastric cancer | Phase 2/3 | Trial Discontinued | Oral | Oncology |
| ASLAN Pharmaceuticals Limited | Eblasakimab (ASLAN004) - (TREK-AD) | Atopic dermatitis (AD) | Phase 2b | Data Released | Subcutaneous | Immunology |
| ASLAN Pharmaceuticals Limited | farudodstat - (FAST-AA) | Alopecia areata (AA) | Phase 2 | Ongoing | oral | Immunology |
| ASLAN Pharmaceuticals Limited | Farudodstat (ASLAN003) | Inflammatory bowel disease (IBD) | Phase 2 | Trial Planned | Oral | Gastroenterology |
| Assembly Biosciences Inc. | AB-729, Vebicorvir (ABI-H0731) and nucleos(t)ide analogue (NA) | Hepatitis B virus (HBV) | Phase 2a | Trial Discontinued | AB-729 subcutaneous Vebicorvir oral nucleos(t)ide analogue oral | Antiviral |
